Regeneron will present Phase 3 data for its ophthalmology product EYLEA HD (aflibercept) Injection 8 mg at the virtual Angiogenesis, Exudation, and Degeneration 2026 meeting on February 7. The data will demonstrate the durability of the 8 mg formulation, including a first every‑two‑month treatment option for retinal vein occlusion and a monthly option for wet age‑related macular degeneration and diabetic macular edema, while maintaining comparable efficacy and safety to the 2 mg version and reducing injection frequency.
The presentation underscores Regeneron’s investment in its eye‑care franchise, a key growth driver. By showcasing durability and reduced injection burden, EYLEA HD could strengthen its competitive position against Roche’s Vabysmo and the impending biosimilar competition for legacy EYLEA, potentially expanding market share and reinforcing the company’s leadership in ophthalmology.
Boaz Hirshberg, Senior Vice President of Clinical Development, said the data will highlight EYLEA HD’s durability and similar efficacy and safety to the 2 mg formulation, supporting the first every‑two‑month treatment option in the setting. CEO Leonard Schleifer noted that Regeneron performed well in 2025, with financial strength driven by four blockbuster medicines and future growth supported by an exciting late‑stage portfolio. CFO Christopher Fenimore added that 2025 was another strong year, marked by notable pipeline advances, remarkable commercial execution, and solid financial performance.
In Q4 2025 Regeneron reported revenue of $3.88 billion and earnings per share of $11.44, beating estimates of $3.76 billion and $10.48. The company guided for increased R&D and SG&A spending in 2026, indicating near‑term margin pressure despite strong product performance. The robust U.S. sales of Dupixent and EYLEA HD offset headwinds from biosimilar competition for legacy EYLEA.
Investors focused on margin pressure from higher operating costs and increased investment guidance, while also noting the strong demand for EYLEA HD. Manufacturing challenges remain, with Regeneron awaiting FDA decisions on a new vial filler and maintaining backup plans for prefilled syringe applications. The data presentation is expected to reinforce confidence in the eye‑care franchise and may influence future pricing and market share dynamics.
The Angiogenesis presentation marks a significant milestone for Regeneron’s ophthalmology portfolio, potentially expanding its market share and reinforcing its competitive edge. The event is a material operational milestone that could shape the company’s revenue trajectory and investor expectations.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.